Landscapes / Targets
PSMA
43 drugs act on PSMA, in 60 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs43
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Approved | 23 Dec 2026Phase 2 trial completes | |||
| Next date | 23 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostatic Neoplasms and 6 more | ||||
| Open drug page | |||||
— |
Approved | Jan 2027Phase 3 trial completes | |||
| Next date | Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | PCA, Prostate Cancer and 6 more | ||||
| Open drug page | |||||
— |
Approved | 25 Apr 2028Phase 3 trial completes | |||
| Next date | 25 Apr 2028 · Phase 3 trial completes | ||||
| Also tested for | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Oligometastatic Prostate Cancer (OMPC) | ||||
| Open drug page | |||||
— |
Phase 3 | 31 Dec 2026Phase 3 trial completes | |||
| Next date | 31 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Prostate Cancer, Prostatic Neoplasms, Castration-Resistant and 6 more | ||||
| Open drug page | |||||
— |
Phase 3 | Mar 2027Phase 3 trial completes | |||
| Next date | Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Prostate Cancer | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Jun 2027Phase 3 trial completes | |||
| Next date | 30 Jun 2027 · Phase 3 trial completes | ||||
| Also tested for | Prostate Cancer (Diagnosis) | ||||
| Open drug page | |||||
— |
Hengrui · Public 600276.SS |
Phase 3 | Dec 2027Phase 3 trial completes | ||
| Next date | Dec 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
— |
Phase 3 | 27 Jun 2028Phase 2/3 trial completes | |||
| Next date | 27 Jun 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Prostate Cancer | ||||
| Open drug page | |||||
— |
Phase 3 | 18 Aug 2028Phase 3 trial completes | |||
| Next date | 18 Aug 2028 · Phase 3 trial completes | ||||
| Also tested for | Prostatic Neoplasms, Metastatic Castration-resistant Prostatic Neoplasms | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Nov 2028Phase 3 trial completes | |||
| Next date | 30 Nov 2028 · Phase 3 trial completes | ||||
| Also tested for | Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | ||||
| Open drug page | |||||
— |
AstraZeneca · Public AZN |
Phase 3 | 4 Jun 2029Phase 3 trial completes | ||
| Next date | 4 Jun 2029 · Phase 3 trial completes | ||||
| Also tested for | Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | ||||
| Open drug page | |||||
— |
Eli Lilly · Public LLY |
Phase 3 | — | ||
| Also tested for | Metastatic Castration-Resistant Prostate Cancer | ||||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Also tested for | Metastasis From Malignant Tumor of Prostate | ||||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Also tested for | Prostate Cancer, Prostate Adenocarcinoma | ||||
| Open drug page | |||||
— |
Phase 2 | 23 Dec 2026Phase 2 trial completes | |||
| Next date | 23 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Metastatic Castration-resistant Prostate Cancer, Metastatic Castration Resistant Prostate Cancer | ||||
| Open drug page | |||||
— |
Phase 1/2 | 31 Dec 2026Phase 1/2 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Jun 2027Phase 1/2 trial completes | |||
| Next date | 30 Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Prostate Cancer | ||||
| Open drug page | |||||
— |
Phase 2 | Aug 2027Phase 2 trial completes | |||
| Next date | Aug 2027 · Phase 2 trial completes | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
Regeneron · Public REGN |
Phase 1/2 | 15 Nov 2027Phase 1/2 trial completes | ||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | 15 Nov 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC) and 2 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 42 of 43 drugs. The other 1 is marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026